基本信息
浏览量:230
职业迁徙
个人简介
Dr. Jean Hoffman-Censits’ research focus is in urothelial cancers. She has had major roles in trials that have established neoadjuvant ddMVAC as a standard therapy for bladder cancer, and which have led to two FDA approvals of Atezolizumab for bladder cancer. Dr. Jean Hoffman-Censits is co-principal investigator on the first major chemotherapy trial in upper tract cancer and has designed a follow-up trial to test immune checkpoint blockade prospectively in this population. She is designing a program in small cell bladder cancer, a rare but aggressive subtype with little prospective data.
研究兴趣
论文共 95 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Clinical Cancer Researchno. 10_Supplement (2024)
Jean Hoffman-Censits,Petros Grivas,Thomas Powles,Jessica Hawley, Karin Tyroller, Sonja Seeberger,Silke Guenther, Natalia Jacob,Keyvan Tadjalli Mehr,Noah M. Hahn
European urology oncology (2024)
Thomas W Flaig, Philippe E Spiess,Michael Abern,Neeraj Agarwal,Rick Bangs,Mark K Buyyounouski,Kevin Chan,Sam S Chang, Paul Chang,Terence Friedlander,Richard E Greenberg,Khurshid A Guru,
Journal of the National Comprehensive Cancer Network : JNCCNno. 4 (2024): 216-225
Burles A. Johnson III, Benjamin A. Teply, Catherine Kagemann,Bridget McGuire,Kara Lombardo,Yuezhou Jing, William Langbo, Jonathan I. Epstein,George J. Netto, Alex S. Baras, Andres Matoso, David J. McConkey,
Bladder Cancerpp.1-11, (2024)
Evangelia Vlachou,Andres Matoso,David McConkey,Yuezhou Jing,Burles Avner Johnson,Noah M. Hahn,Jean Hoffman-Censits
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
The Canadian journal of urologyno. 3 (2023): 11526-11531
引用0浏览0WOS引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn